| No. Vertebral fractures | No. Non-Vertebral Fractures | ||
---|---|---|---|---|
 | Coefficient | P-value | Coefficient | P-value |
Age | 0.035 | 0.072 | -0.005 | 0.788 |
Height | -0.034 | 0.010 | -0.017 | 0.164 |
Weight | 0.007 | 0.523 | 0.015 | 0.155 |
Iliocostal distance | -0.259 | 0.095 | -0.037 | 0.796 |
Lumbar spine BMD | -2.360 | 0.174 | -0.399 | 0.779 |
Femoral neck BMD | -1.378 | 0.511 | -0.106 | 0.953 |
Trochanter BMD | -1.728 | 0.410 | -0.822 | 0.646 |
Ward's triangle BMD | -2.138 | 0.196 | 0.275 | 0.846 |
Prevalent vertebral fractures | NA | Â | 0.396 | 0.361 |
Prevalent non-vertebral fractures | -0.090 | 0.851 | NA | Â |
Currently smoking | 0.036 | 0.876 | 0.161 | 0.443 |
Family history of fracture | -0.538 | 0.330 | -0.647 | 0.184 |
Alcohol-beverages/week | -0.002 | 0.933 | 0.043 | 0.079 |
No. of falls | 0.691 | 0.002 | 0.561 | 0.006 |
Calcium intake-mg/d | 0.001 | 0.028 | 0.000 | 0.600 |
Exercise-min/week | -0.000 | 0.683 | -0.001 | 0.484 |
Etidronate use | 0.259 | 0.574 | -0.180 | 0.665 |
Alendronate use | 0.589 | 0.038 | 0.036 | 0.891 |
Fluoride use | NA | Â | NA | Â |
Raloxifene use | NA | Â | NA | Â |
Hormone replacement use | NA | Â | NA | Â |
Corticosteroids use | -0.479 | 0.286 | 0.000 | 1.000 |
Calcium supplement use | -0.014 | 0.972 | -0.370 | 0.279 |
Vitamin D supplement use | 0.010 | 0.977 | 0.000 | 1.000 |
Lung diseasea | -0.921 | 0.315 | 0.000 | 1.000 |
Liver diseaseb | 1.205 | 0.276 | 1.051 | 0.292 |
Thyroid diseasec | NA | Â | NA | Â |
Cancerd | NA | Â | NA | Â |
Visual impairment | -0.257 | 0.810 | 1.635 | 0.082 |
Osteoporosis | 1.003 | 0.046 | 0.113 | 0.809 |
Inflammatory bowel disease | -0.517 | 0.480 | 0.000 | 1.000 |
Epilepsy | -0.897 | 0.419 | -1.051 | 0.292 |
Coronary disease | -0.875 | 0.574 | 0.000 | 1.000 |
Cerebrovascular disease | 3.225 | 0.033 | 3.075 | 0.024 |
Rheumatoid arthritis | NA | Â | NA | Â |
Diabetes | NA | Â | NA | Â |
Kidney failure | NA | Â | NA | Â |